Centro Andaluz de Biología del Desarrollo -ko ikertzaileekin lankidetzan egindako argitalpenak (49)

2024

  1. A Multi-Target Pharmacological Correction of a Lipoyltransferase LIPT1 Gene Mutation in Patient-Derived Cellular Models

    Antioxidants, Vol. 13, Núm. 8

  2. Polydatin and Nicotinamide Rescue the Cellular Phenotype of Mitochondrial Diseases by Mitochondrial Unfolded Protein Response (mtUPR) Activation

    Biomolecules, Vol. 14, Núm. 5

  3. The impact and future of artificial intelligence in medical genetics and molecular medicine: an ongoing revolution

    Functional and Integrative Genomics, Vol. 24, Núm. 4

2023

  1. Actin Polymerization Defects Induce Mitochondrial Dysfunction in Cellular Models of Nemaline Myopathies

    Antioxidants, Vol. 12, Núm. 12

  2. Mitochondrial Quality Control via Mitochondrial Unfolded Protein Response (mtUPR) in Ageing and Neurodegenerative Diseases

    Biomolecules, Vol. 13, Núm. 12

  3. Neurodegeneration, Mitochondria, and Antibiotics

    Metabolites, Vol. 13, Núm. 3

  4. Patient-Derived Cellular Models for Polytarget Precision Medicine in Pantothenate Kinase-Associated Neurodegeneration

    Pharmaceuticals, Vol. 16, Núm. 10

  5. Vicious cycle of lipid peroxidation and iron accumulation in neurodegeneration

    Neural Regeneration Research, Vol. 18, Núm. 6, pp. 1196-1202

  6. mtUPR Modulation as a Therapeutic Target for Primary and Secondary Mitochondrial Diseases

    International Journal of Molecular Sciences, Vol. 24, Núm. 2

2022

  1. Activation of the Mitochondrial Unfolded Protein Response: A New Therapeutic Target?

    Biomedicines, Vol. 10, Núm. 7

  2. Modeling Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-Like Episodes Syndrome Using Patient-Derived Induced Neurons Generated by Direct Reprogramming

    Cellular reprogramming, Vol. 24, Núm. 5, pp. 294-303

  3. Pterostilbene in Combination With Mitochondrial Cofactors Improve Mitochondrial Function in Cellular Models of Mitochondrial Diseases

    Frontiers in Pharmacology, Vol. 13

  4. Therapeutic approach with commercial supplements for pantothenate kinase-associated neurodegeneration with residual PANK2 expression levels

    Orphanet journal of rare diseases, Vol. 17, Núm. 1, pp. 311

2021

  1. Coenzyme q10 analogues: Benefits and challenges for therapeutics

    Antioxidants, Vol. 10, Núm. 2, pp. 1-20

  2. EGFR-targeting antitumor therapy: Neuregulins or antibodies?

    European Journal of Pharmaceutical Sciences, Vol. 158

  3. From mitochondria to atherosclerosis: The inflammation path

    Biomedicines, Vol. 9, Núm. 3, pp. 1-24

  4. Mitochondria and antibiotics: For good or for evil?

    Biomolecules, Vol. 11, Núm. 7

2020

  1. Coenzyme q10: Novel formulations and medical trends

    International Journal of Molecular Sciences, Vol. 21, Núm. 22, pp. 1-23

  2. Mitochondrial imbalance as a new approach to the study of fibromyalgia

    Open Access Rheumatology: Research and Reviews, Vol. 12, pp. 175-185

2019

  1. PARL deficiency in mouse causes Complex III defects, coenzyme Q depletion, and Leigh-like syndrome

    Proceedings of the National Academy of Sciences of the United States of America, Vol. 116, Núm. 1, pp. 277-286